Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) have been given an average recommendation of “Moderate Buy” by the ten analysts that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $41.00.

Several research firms have issued reports on OLMA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research report on Thursday, January 22nd. Citigroup upped their target price on shares of Olema Pharmaceuticals from $21.00 to $60.00 and gave the company a “buy” rating in a report on Friday, December 12th. The Goldman Sachs Group raised their target price on shares of Olema Pharmaceuticals from $26.00 to $38.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. JPMorgan Chase & Co. boosted their price target on Olema Pharmaceuticals from $29.00 to $32.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 18th. Finally, Piper Sandler began coverage on Olema Pharmaceuticals in a research note on Wednesday, January 7th. They issued an “overweight” rating and a $40.00 price objective on the stock.

Olema Pharmaceuticals Stock Down 6.3%

OLMA stock opened at $23.37 on Friday. The company has a quick ratio of 8.03, a current ratio of 8.03 and a debt-to-equity ratio of 0.01. The business has a 50 day moving average price of $27.30 and a two-hundred day moving average price of $15.91. The company has a market cap of $1.60 billion, a price-to-earnings ratio of -12.50 and a beta of 1.89. Olema Pharmaceuticals has a twelve month low of $2.86 and a twelve month high of $36.26.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.05). Analysts anticipate that Olema Pharmaceuticals will post -2.33 EPS for the current fiscal year.

Insiders Place Their Bets

In other Olema Pharmaceuticals news, insider David C. Myles sold 50,000 shares of the company’s stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $27.60, for a total value of $1,380,000.00. Following the transaction, the insider directly owned 542,761 shares in the company, valued at $14,980,203.60. The trade was a 8.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Cyrus Harmon sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $26.88, for a total transaction of $268,800.00. Following the sale, the director owned 727,770 shares of the company’s stock, valued at approximately $19,562,457.60. This represents a 1.36% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 765,501 shares of company stock worth $22,052,432 in the last quarter. Insiders own 16.36% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of OLMA. Ameritas Investment Partners Inc. lifted its position in Olema Pharmaceuticals by 55.4% during the second quarter. Ameritas Investment Partners Inc. now owns 6,080 shares of the company’s stock worth $26,000 after acquiring an additional 2,168 shares during the last quarter. Farther Finance Advisors LLC increased its stake in shares of Olema Pharmaceuticals by 602.9% during the second quarter. Farther Finance Advisors LLC now owns 6,839 shares of the company’s stock worth $29,000 after purchasing an additional 5,866 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in Olema Pharmaceuticals by 9,476.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock worth $31,000 after purchasing an additional 1,232 shares during the last quarter. FNY Investment Advisers LLC boosted its stake in Olema Pharmaceuticals by 100.0% in the 2nd quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company’s stock valued at $42,000 after purchasing an additional 5,000 shares during the period. Finally, Torren Management LLC bought a new stake in Olema Pharmaceuticals in the 4th quarter valued at $44,000. 91.78% of the stock is owned by institutional investors.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.